Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — H.C. Wainwright Global Investment Conference 2026
21 slides from Cantargia Ab's conference presentation, Sep 14, 2026
Slide 1: Blocking the RIGHT signals to improve treatment options
Blocking the RIGHT signals to improve treatment options HCW Presentation September 2026 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve know
Slide 3: Cantargia Is the Preeminent IL1RAP-Focused Company
Cantargia Is the Preeminent IL1RAP-Focused Company → IL1 Receptor Accessory Protein (IL1RAP) is a co-receptor required for downstream signaling of IL-1, IL-33 and IL-36 → Targeting IL1RAP impacts three signaling systems to counteract redundancy and increase efficacy → IL1RAP biology links innate and
Slide 4: Our IL1RAP-Focused Pipeline
Our IL1RAP-Focused Pipeline Asset Target Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Partner Oncology PDAC + Daraxonrasib - Phase 1b Nadunolimab IL1RAP MDS/AML1 Investigator-Initiated Trial Autoimmune CAN14 IL1RAP BsAb3 Autoimmune diseases CAN10 IL1RAP Autoimmune diseases Otsuka acquire
Slide 5: Executive Management Team with Extensive Experience
Executive Management Team with Extensive Experience Hilde Steineger Patrik Renblad David Liberg Ton Berkien CEO CFO CSO CBO EXECUTIVE TEAM WITH COMPREHENSIVE INDUSTRY INSIGHT 5
Slide 6: Myeloid Malignancies – MDS and AML
MYELOID MALIGNANCIES – MDS AND AML
Slide 7: Nadunolimab Targets the Cells Chemotherapy Leaves Behind
Nadunolimab Targets the Cells Chemotherapy Leaves Behind Leukemic stem cells survive chemotherapy and seed relapse. IL1RAP is what makes them targetable. 1 A target that healthy cells do not carry IL1RAP is expressed on leukemic stem cells in AML and high-risk MDS, but not on normal hematopoietic st
Slide 8: Two Presentations of the Same IL1RAP-Driven Disease
Two Presentations of the Same IL1RAP-Driven Disease The same leukemic stem cells drive both. What separates them is blast burden and how far the disease has run. Myelodysplastic syndrome Acute myeloid leukemia 30-40% ~400k global prevalence1 of high-risk MDS becomes AML ~204k global prevalence 10-30
Slide 9: IIT at MD Anderson: Ph1b/2a Study in MDS/AML
IIT at MD Anderson: Ph1b/2a Study in MDS/AML Principal Investigator: Gautam Borthakur, MD, MD Anderson Cancer Center Grant support: U.S. Department of Defense (DOD) Study start 2025 Arm 1 HR-MDS (n=20): Cycle 1 Cycle 2-24 • Intermediate/high/very high risk MDS* • Untreated or up to 2 Treatment prior
Slide 10: Pancreatic Ductal Adenocarcinoma – PDAC
PANCREATIC DUCTAL ADENOCARCINOMA – PDAC
Slide 11: PDAC: A Deadly Cancer with Limited Treatment Options, Now a New Starting Point
PDAC: A Deadly Cancer with Limited Treatment Options, Now a New Starting Point The lines of therapy have changed. Second line is now a targeted setting. ~230k ~140k ~85k 8.5 – 11.7 mths Diagnosed incident cases Advanced or metastatic Treated in the 1L median overall survival, per year, 8 markets¹ di
Slide 12: CANFOUR: Nadunolimab Plus Chemotherapy in Metastatic PDAC
CANFOUR: Nadunolimab Plus Chemotherapy in Metastatic PDAC Phase 1/2a of nadunolimab with gemcitabine and nab-paclitaxel in advanced, metastatic disease. Overall survival versus chemotherapy alone Nadunolimab + gem / nab-P CANFOUR¹ 13.2 mths Chemotherapy alone NAPOLI-32 9.2 mths Chemotherapy alone MP
Slide 13: IL1RAP Marks the Worst Prognosis in PDAC, and Nadunolimab Inverts the Curves
IL1RAP Marks the Worst Prognosis in PDAC, and Nadunolimab Inverts the Curves Untreated: high IL1RAP means shorter survival Treated with nadunolimab: the curves flip → In the Know Your Tumor dataset, PDAC patients with high IL1RAP → With nadunolimab plus chemotherapy, IL1RAP-high patients lived expre
Slide 14: Future of PDAC Management – Two Targetable Pathways with Strong Combination Potential
Future of PDAC Management – Two Targetable Pathways with Strong Combination Potential → KRAS fuels IL-1 dependent tumor inflammation → Autocrine IL-1 activates IL1RAP and triggers tumor cell intrinsic IRAK-dependent signaling → IL-1 signaling shapes the TME by activating IL1RAP on myeloid cells and
Slide 15: Preparing the Phase 1b of Nadunolimab with Daraxonrasib in 2L PDAC
Preparing the Phase 1b of Nadunolimab with Daraxonrasib in 2L PDAC An open-label Phase 1b assessing safety and tolerability of nadunolimab with daraxonrasib in adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, the population in the daraxonrasib l
Slide 16: CANxx, CAN10 and CAN14
CANxx, CAN10 and CAN14 One platform, one partnered asset, one next-generation program CANxx is Cantargia's platform of anti-IL1RAP antibodies, reagents and know-how. CAN10 came out of the platform and was acquired by Otsuka, which validates IL1RAP as a target in inflammation. CAN14 is the second pro
Slide 17: CANxx: The Engine Behind Nadunolimab and CAN10
CANxx: The Engine Behind Nadunolimab and CAN10 An anti-IL1RAP antibody library and the know-how to turn it into drug candidates. ~500 2 $30bn $20bn Anti-IL1RAP Clones Clinical Stage Programs Bispecific Market ADC Segment Growth in the Library1 Generated so Far Expansion by 20302 2025 to 20303 The Pl
Slide 18: Transformational CAN10 Deal with Otsuka
Transformational CAN10 Deal with Otsuka External validation of the IL1RAP platform → Otsuka acquired global rights to CAN10, validating IL1RAP as a target in inflammation and the platform that produced it USD 613M Total potential deal value Commercial proof point outside oncology → Demonstrates the
Slide 19: The Next Generation of IL1RAP Therapeutics: CAN14 and ADCs
The Next Generation of IL1RAP Therapeutics: CAN14 and ADCs Three cytokines, one molecule Two ways to drug the same target IL1RAP is the shared co-receptor A bispecific antibody for inflammation, and a targeted payload for oncology IL-1 CAN14 · BISPECIFIC ANTIBODY IL1RAP ADCs · TARGETED PAYLOAD WHAT
Slide 20: Upcoming Catalysts
Upcoming Catalysts A Global Leader in IL1RAP Antibody Development Year-end 2026 Q1 2027 Mid-2027 MDS/AML interim data PDAC Phase 1b of MDS/AML Phase 2a presented at ASH 2026 nadunolimab with completes at MD Anderson, CAN14 second target daraxonrasib initiated data to follow disclosed subject to regu
Slide 21: Thank you
Thank you Contact details: info@cantargia.com
Cantargia — H.C. Wainwright Global Investment Conference 2026 on 6ix